J&J makes a splash in hep C with a $1.75B deal for Alios
September 30, 2014 | By Damian Garde
Johnson & Johnson ($JNJ) is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.
The handsome deal is an all-cash transaction that will bring J&J a wide pipeline of nucleotide analogs, or nucs, oral treatments that stop viral infections by blocking their ability to reproduce.
The handsome deal is an all-cash transaction that will bring J&J a wide pipeline of nucleotide analogs, or nucs, oral treatments that stop viral infections by blocking their ability to reproduce.
No comments:
Post a Comment